Pharmacology 3620 Lecture Notes - Lecture 9: Vitamin K Epoxide Reductase, Cyp2D6, Cyp2C9

• School: Western University
• Department: Pharmacology
• Course: Pharmacology 3620
• Professor: Rommel Tirona

Document Summary

Precision medicine: an emerging approach for disease prevention and treatment that takes i(cid:374)to a(cid:272)(cid:272)ou(cid:374)t people(cid:859)s i(cid:374)di(cid:448)idual (cid:448)a(cid:396)iatio(cid:374)s i(cid:374) ge(cid:374)es, e(cid:374)(cid:448)i(cid:396)o(cid:374)(cid:373)e(cid:374)t a(cid:374)d lifestyle. Drugs used to be designed with the average patient in mind, now they can be tailored to spe(cid:272)ifi(cid:272) patie(cid:374)t(cid:859)s genetics, microbes, and chemical composition. Phase i drug metabolizing enzymes: cyp2d6, cyp2c9. Phase ii drug metabolizing enzymes: tpmt, ugt1a1. Drug targets: 1 adrenergic receptor, vitamin k epoxide reductase complex i. Metabolizes approximately 25% of all drugs on the market. Variable response was originally described by two independent laboratories at the same time. Cyp2d6 is one of the prototypical examples in pharmacogenetics as there exists snps, ins/dels and copy number variations. There are over 90 known allelic variants in cyp2d6. Polymorphisms in drug metabolizing enzymes like cyp2d6 are often referred to by the (cid:862)*(cid:863) (cid:374)o(cid:373)e(cid:374)(cid:272)latu(cid:396)e. Cyp2d6*1 represents the wild-type sequence whereas cyp2d6*3 has an a2367del. The star nomenclature often represents more than one polymorphism: e. g.